Today's Trend
Voyager Therapeutics, Inc. (NASDAQ: VYGR) received a broadly positive analyst update from HC Wainwright, which reaffirmed its Buy rating and raised EPS forecasts across 2026–2030. The revisions suggest the analyst expects narrower losses than previously projected, providing a potential catalyst for the stock.
- HC Wainwright raised its FY2026 EPS forecast to a loss of $1.32 from $1.61 and increased its FY2027 estimate to a loss of $1.06 from $1.18. Quarterly estimates were also improved, including Q3 2026 to a loss of $0.29 from $0.39 and Q4 2026 to a loss of $0.17 from $0.27.
- The analyst also reduced projected losses for FY2028, FY2029 and FY2030 to $1.17, $0.98 and $0.55 per share, respectively, versus prior estimates of $1.63, $1.38 and $0.94. This implies a more favorable long-term earnings trajectory, although profitability is still not expected in those periods. HC Wainwright Reaffirms Buy Rating for Voyager Therapeutics
- Despite the improved forecasts, Voyager remains an unprofitable biotechnology company, and the revisions are based on analyst expectations rather than new clinical, regulatory or partnership announcements. Investors should continue to watch cash resources, development milestones and future financing needs.
The updated outlook is likely supporting sentiment toward VYGR, but the shares remain near the lower end of their 52-week range and below their 50-day and 200-day moving averages, indicating that technical momentum remains weak.